APRINOIA Therapeutics Announces Mutual Termination of Business Combination Agreement with ROSS Acquisition Corp II
August 23, 2023 17:21 ET
|
APRINOIA Therapeutics, Inc.
CAMBRIDGE, Mass., Aug. 23, 2023 (GLOBE NEWSWIRE) -- APRINOIA Therapeutics (“APRINOIA”), a global clinical-stage biopharmaceutical company developing novel therapeutics and precision diagnostics for...
Neuronascent Announces NIA Grant Award for NNI-362 to Reach Phase 2 Clinical Trials for Mild to Moderate Alzheimer’s Disease
August 22, 2023 06:00 ET
|
Neuronascent, Inc.
ROCKVILLE, Md., Aug. 22, 2023 (GLOBE NEWSWIRE) -- Neuronascent Inc., a privately-held neuron regeneration therapeutics company, today announced that the National Institute of Aging (NIA), has...
Deep Brain Stimulation Market worth $1.15 Billion by 2030 - Exclusive Report by The Insight Partners
August 16, 2023 08:37 ET
|
The Insight Partners
Pune, India, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Deep brain stimulator (DBS) is a device comprising a brain-oriented pacemaker (an implantable pulse generator) that sends electrical stimulation via...
Alzheimer’s Disease Biomarkers Market Predicted to Reach USD 1.7 billion by 2031, Expanding at a 7.5% CAGR Says, Transparency Market Research Inc.
August 14, 2023 07:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global Alzheimer’s disease biomarkers market is expected to be valued at US$ 953.54...
Alzheimer's Disease Market Predicted to Surge at a CAGR of 20% During the Study Period (2019–2032), Assesses DelveInsight
August 02, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Alzheimer's Disease Market Predicted to Surge at a CAGR of 20% During the Study Period (2019–2032), Assesses DelveInsight The Alzheimer's disease...
The Joint Commission, in Collaboration with the Alzheimer’s Association, Launches Memory Care Certification for Assisted Living Communities
July 11, 2023 12:30 ET
|
The Joint Commission
OAKBROOK TERRACE, Ill., July 11, 2023 (GLOBE NEWSWIRE) -- The Joint Commission, in collaboration with the Alzheimer’s Association, launched Memory Care Certification for Assisted Living Communities...
Neuronascent to Present New Parkinson’s Model Data at AAIC 2023 for the Alzheimer’s Disease Investigational Therapy, NNI-362
June 28, 2023 06:00 ET
|
Neuronascent, Inc.
ROCKVILLE, Md., June 28, 2023 (GLOBE NEWSWIRE) -- Neuronascent Inc., today announced its abstract titled, Clinical Stage Alzheimer’s therapy, NNI-362 Promotes TH+ Neurons Associated with a Reversal...
Landmark Study Investigating Novel Alzheimer’s Biomarkers Advances to Data Analysis Stage
June 14, 2023 06:00 ET
|
Global Alzheimer's Platform Foundation
WASHINGTON, DC, June 14, 2023 (GLOBE NEWSWIRE) -- Up to 50 percent of people in the U.S. with Alzheimer’s receive an imprecise or inaccurate diagnosis of their cognitive condition. The tools...
Vaccinex, Inc. to Participate in the Jefferies Healthcare Conference Track 6, on Friday, June 9, 2023 at 10:00 to 10:25 a.m. ET
June 01, 2023 08:00 ET
|
Vaccinex, Inc.
ROCHESTER, N.Y., June 01, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease...
Vaccinex New ActivMAb® application published in Nature Communications for Directed Evolution of GPCRs in Mammalian Cells
April 12, 2023 08:00 ET
|
Vaccinex, Inc.
GPCRs play a key role in many important physiological processes which makes them an important class of drug targets; however, their biophysical properties have made many GPCRs “difficult to drug” New...